On Nov. 6, the U.S. Food and Drug Administration (FDA) approved Xeljanz (tofacitinib) to treat adults with moderately to severely active rheumatoid arthritis who have had an inadequate response to, or who are intolerant of, methotrexate. Read more.
FDA approves Xeljanz for rheumatoid arthritis
Author(s):
Most Recent Content
For Nurse Practitioners
Menopause and Sleep Problems
Data shows that sleep disturbances increase in prevalence during the menopausal transition, with the most common complaint being nighttime awakenings.
Take our quick three-question survey...
